Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Summary

The purpose of this study is to study efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease

Timeline

Start

2008-05

Primary completion

2008-12

Completion

2008-12

Outcome

Missed primary endpoint

paper for the co-primary endpoints of pre-bronchodilator FEV1 (AZD1981-placebo: -0.015, 95% CI: -0.10 to 0.070; p = 0.72) PMID 23827726 ↗

paper and CCQ total score (difference: 0.042, 95% CI: -0.21 to 0.30; p = 0.75). PMID 23827726 ↗

Publications

• Snell N, Foster M, Vestbo J. Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. Respir Med. 2013 Nov;107(11):1722-30. doi: 10.1016/j.rmed.2013.06.006. Epub 2013 Jul 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD1981	Small molecule	1000 mg	Oral

Indications